Fosmetpantotenate

Summary

Fosmetpantotenate (CHEMBL6067991) is a phase-3 clinical-stage unknown; indicated across 1 condition including pantothenate kinase-associated neurodegeneration.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6067991
Name	Fosmetpantotenate
Type	Unknown
Max phase	3

Also known as: Fosmetpantotenate, Fosmetpantotenato, RE-024, FOSMETPANTOTENATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
pantothenate kinase-associated neurodegeneration	3	MONDO:0009319	MONDO:0009319

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03041116	PHASE3	TERMINATED	Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).